Loading people...
Kazumi Shiosaki is the Boston-based CEO of Redona Therapeutics and a Managing Director at MPM BioImpact. She previously served as the founding CEO of Mitobridge, guiding the biotechnology startup until its acquisition by Astellas Pharma for up to $450 million in 2017. Shiosaki also co-founded and led Epizyme, which completed an initial public offering, and launched Twentyeight-Seven Therapeutics with a $65 million Series A round in 2018. Earlier in her career, she worked as Senior Vice President of Drug Discovery at Millennium Pharmaceuticals and earned a doctorate in synthetic chemistry from UC Berkeley. Additionally, she serves as an independent director at Enthera Pharmaceuticals and sits on the board of the Sanford Burnham Institute. Her current focus remains centered on early-stage life sciences venture capital investments and leading drug discovery startups targeting novel epigenetic therapeutics.
Kazumi Shiosaki stands as a distinguished Managing Partner at MPM Capital, a leading venture capital firm renowned for its deep commitment to advancing life sciences. At MPM Capital, Kazumi plays a critical role in shaping the future of medicine by identifying, funding, and nurturing innovative biotechnology companies. Her investment focus is primarily on novel therapeutics, spanning critical areas such as oncology, immunology, and rare diseases, where there remains significant unmet medical need.
Her strategic vision and deep industry knowledge are instrumental in MPM Capital's success in company creation. Kazumi is actively involved in building companies from the ground up, working closely with scientific founders and management teams to translate cutting-edge research into viable therapeutic solutions. This hands-on approach ensures that portfolio companies are well-positioned for success, from early-stage development through clinical trials and beyond.
Before joining MPM Capital in 2005, Kazumi honed her expertise in various capacities within the life sciences investment landscape. She served as a Principal at Bay City Capital, where her focus was on private equity investments across the life sciences sector. Prior to her venture capital roles, Kazumi was a consultant at McKinsey & Company, providing strategic guidance to pharmaceutical and biotechnology companies on complex business challenges. This diverse background equipped her with a comprehensive understanding of both the scientific and commercial aspects of drug development.
Kazumi's academic foundation is equally robust, holding an MBA from Stanford University Graduate School of Business and a BA in Chemistry from Princeton University. Her blend of scientific acumen and business insight makes her a formidable force in the venture capital world.
Throughout her tenure at MPM Capital, Kazumi Shiosaki has been a key driver in numerous successful investments and company builds. Her board roles have included influential companies such as Werewolf Therapeutics (NASDAQ: HOWL), Orna Therapeutics, ReNAgade Therapeutics, ElevateBio, Triplet Therapeutics, and NextPoint Therapeutics. She was also instrumental in the success of Maverick Therapeutics (acquired by Takeda), Potenza Therapeutics (acquired by Astellas), and TCR2 Therapeutics (acquired by Adaptimmune), demonstrating her ability to identify and scale companies that deliver significant value and therapeutic impact. Her leadership continues to propel MPM Capital's mission to invest in transformative biomedical innovation.
Kazumi Shiosaki is a Managing Partner at MPM Capital, a prominent venture capital firm specializing in life sciences and biotech investments.
Kazumi Shiosaki primarily invests in groundbreaking biotech companies focused on novel therapeutics, particularly in areas like oncology, immunology, and rare diseases. She is also deeply involved in company creation and early-stage investments.
Kazumi Shiosaki works as a Managing Partner at MPM Capital, a leading venture capital firm dedicated to advancing life sciences.
